Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2007 Dec;31(6):729-34.
doi: 10.1007/s00264-007-0418-6. Epub 2007 Jul 17.

A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft)

William F McKay  1 , Steven M Peckham, Jeffrey M Badura
Affiliations
Review

A comprehensive clinical review of recombinant human bone morphogenetic protein-2 (INFUSE Bone Graft)

William F McKay et al. Int Orthop. 2007 Dec.

Abstract
in English, French

The combination of recombinant human bone morphogenetic protein-2 (rhBMP-2) on an absorbable collagen sponge (ACS) carrier has been shown to induce bone formation in a number of preclinical and clinical investigations. In 2002, rhBMP-2/ACS at a 1.5-mg/cc concentration (INFUSE Bone Graft, Medtronic Spinal and Biologics, Memphis, TN) was FDA-approved as an autograft replacement for certain interbody spinal fusion procedures. In 2004, INFUSE Bone Graft was approved for open tibial fractures with an intermedullary (IM) nail fixation. Most recently, in March 2007, INFUSE Bone Graft was approved as an alternative to autogenous bone grafts for sinus augmentations, and for localised alveolar ridge augmentations for defects associated with extraction sockets. The culmination of extensive preclinical and clinical research and three FDA approvals makes rhBMP-2 one of the most studied, published and significant advances in orthopaedics. This review article summarises a number of clinical findings of rhBMP-2/ACS, including the FDA-approved investigational device exemption (IDE) studies used in gaining the aforementioned approvals.

L’utilisation de la BMP (rhBPM-2) sur une éponge de collagène a des effets positifs sur l’ostéogénèse. En 2002, ce produit avec un dosage de 1.5 mg/cc (INFUSE® Bone Graft, Medtronic Spinal and Biologics, Memphis, Tenn), a été approuvé par la FDA comme un supplétif de l’auto greffe pour, certains cas d’arthrodèses rachidiennes. En 2004 ce produit (INFUSE®) a également été approuvé par la FDA pour les fractures ouvertes de jambes, traitées par clous centro-médullaires. De façon plus récente, en mars 2007, ce produit a été également autorisé comme une alternative au traitement des ostéolyses et défects osseux associés à l’ablation d’une cupule cotyloïdienne. L’association de ces autorisations et des recherches cliniques et pré-cliniques sur la rhBMP-2 permettent une avance significative des connaissances en chirurgie orthopédique ainsi que la revue des différents travaux et des autorisations de la FDA.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
INFUSE® Bone Graft kits and contents. All four kits (small, medium, large and large II) are FDA-approved for the spine and oral maxillofacial applications, while only the large II kit is approved for orthopaedic trauma applications
Fig. 2
Fig. 2
Sample computed tomography (CT) scans showing the efficacy of INFUSE® Bone Graft in each of the three approved indications
See this image and copyright information in PMC

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1097/00007632-200306150-00003', 'is_inner': False, 'url': 'https://doi.org/10.1097/00007632-200306150-00003'}, {'type': 'PubMed', 'value': '12811263', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12811263/'}]}
    2. Baskin DS, Ryan P, Sonntag V, Westmark R, Widmayer MA (2003) A prospective, randomized, controlled cervical fusion study using recombinant human bone morphogenetic protein-2 with the CORNERSTONE-SR allograft ring and the ATLANTIS anterior cervical plate. Spine 28(12):1219–1225 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '12473698', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/12473698/'}]}
    2. BESTT Study Group, Govender S, Csimma C, Genant HK, Valentin-Opran A et al (2002) Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84(12):2123–2134 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '10332250', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/10332250/'}]}
    2. Boyne PJ, Marx RE, Nevins M, Triplett G, Lazaro E, Lilly LC, Alder M, Nummikoski P (1997) A feasibility study evaluating rhBMP-2/absorbable collagen sponge for maxillary sinus floor augmentation. Int J Periodontics Restorative Dent 17(1):11–25 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '11314792', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/11314792/'}]}
    2. Boyne PJ (2001) Application of bone morphogenetic proteins in the treatment of clinical oral and maxillofacial osseous defects. J Bone Joint Surg Am 83:146–150 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1016/j.joms.2005.08.018', 'is_inner': False, 'url': 'https://doi.org/10.1016/j.joms.2005.08.018'}, {'type': 'PubMed', 'value': '16297689', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/16297689/'}]}
    2. Boyne PJ, Lilly LC, Marx RE, Moy PK, Nevins M, Spagnoli DB, Triplett RG (2005) De novo bone induction by recombinant human bone morphogenetic protein-2 (rhBMP-2) in maxillary sinus floor augmentation. J Oral Maxillofac Surg 63:1693–1707 - PubMed

MeSH terms

Substances